Core Viewpoint - FibroBiologics has completed onboarding clinical sites for its Phase 1/2 clinical trial of CYWC628, aimed at treating refractory diabetic foot ulcers (DFUs) [1][2]. Group 1: Clinical Trial Details - The clinical trial is a prospective, multicenter, open-label study designed to evaluate the safety, tolerability, and efficacy of CYWC628, which is a topically administered allogeneic fibroblast spheroid-based therapy [2][8]. - Participants will undergo up to 12 weeks of treatment, receiving either standard of care (SoC) plus a low or high dose of CYWC628, or SoC alone [2][8]. - An interim analysis will be conducted after a predefined number of participants complete six weeks of treatment to assess primary safety and efficacy endpoints [3]. Group 2: Company Statements and Management - The successful engagement of all clinical trial sites is seen as a critical step towards trial initiation, with a focus on disciplined execution to demonstrate the potential of fibroblast spheroid-based therapies [4]. - Southern Star Research, a full-service Australian CRO, is managing all aspects of the CYWC628 trial, emphasizing the program's fit within Australia's clinical research ecosystem [4][10]. Group 3: Product Information - CYWC628 is an investigational therapy that may significantly accelerate wound healing compared to currently available treatments, based on preclinical data [7][8]. - FibroBiologics holds over 270 patents issued and pending, focusing on developing therapeutics for chronic diseases using fibroblast cells and fibroblast-derived materials [9].
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers